Verition Fund Management’s Edgewise Therapeutics EWTX Stock Holding History

Verition Fund Management’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$406K	Buy	+10,000	New	+$345K	﹤0.01%	1695
2026 Q1	–	Sell	-33,591	Closed	-$834K	–	2687
2025 Q4	$834K	Buy	+33,591	New	+$674K	﹤0.01%	2296
2025 Q3	–	Sell	-44,069	Closed	-$578K	–	3831
2025 Q2	$578K	Buy	44,069 +9,350	+27%	+$135K	﹤0.01%	2847
2025 Q1	$764K	Sell	34,719 -11,672	-25%	-$306K	﹤0.01%	2316
2024 Q4	$1.24M	Buy	+46,391	New	+$1.48M	﹤0.01%	1904
2024 Q3	–	Sell	-44,783	Closed	-$807K	–	3281
2024 Q2	$807K	Buy	+44,783	New	+$781K	﹤0.01%	1806

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Verition Fund Management's EWTX Position: Q2 2026 in Review

Verition Fund Management opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 10,000 shares worth $406K. The stake represents ﹤0.01% of the portfolio and ranks #1695 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in EWTX as recently as Q4 2025.

Verition Fund Management first reported a position in EWTX in Q2 2024 and has held it in 6 quarters since. The position peaked at $1.24M in Q4 2024. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

Verition Fund Management held 10,000 shares of Edgewise Therapeutics worth $406K as of Q2 2026.
Edgewise Therapeutics was a new Verition Fund Management position in Q2 2026.
Edgewise Therapeutics made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1695 holding.
Verition Fund Management first reported a position in Edgewise Therapeutics in Q2 2024 and has held it in 6 quarters since.
Verition Fund Management's Edgewise Therapeutics position peaked at $1.24M in Q4 2024.
223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.